Clinical trial
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants…
NCT00171951 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171951 |
|---|---|
| Title | Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease |
| Official title | Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cushing Disease |
| Intervention type | Drug |
| Interventions | Pasireotide |
| Enrollment | 19 |
| Start date | Aug 13, 2004 |
| Primary completion | Jul 8, 2013 |
| Completion | Jul 8, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | Jun 2, 2021 |
| Countries | France, Germany, Italy, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: